4,5 OBODENCE and XBRYK, marking Samsung Bioepis’ 10 th and 11 th EC approvals as well as the company’s first EC approval for an endocrinology biosimilar, add to the company’s growing portfolio in new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback